Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levorphanol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 5/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.82 |
| ▸ | GRIN2A | Q12879 | 7/20 | 0.82 |
| ▸ | GRIN2D | O15399 | 6/20 | 0.82 |
| ▸ | GRIN3B | O60391 | 6/20 | 0.82 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.82 |
| ▸ | GRIN2C | Q14957 | 6/20 | 0.82 |
| ▸ | GRIN3A | Q8TCU5 | 6/20 | 0.82 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.82 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.82 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.82 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.82 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dextrorphan SCHEMBL728534 | 1.00 | CYP2D6 (1.00) | CYP2D6MAPTBLMLMNAHTT | |
| Dextrorphan SCHEMBL30546365 | 1.00 | CYP2D6 (1.00) | CYP2D6MAPTBLMLMNAHTT | |
| Levorphanol SCHEMBL17598076 | 0.99 | CYP2D6 (0.98) | CYP2D6MAPTBLMLMNAHTT | |
| Levorphanol SCHEMBL29363177 | 0.99 | CYP2D6 (0.98) | CYP2D6MAPTBLMLMNAHTT | |
| Levorphanol SCHEMBL194174 | 0.99 | CYP2D6 (0.98) | CYP2D6MAPTBLMLMNAHTT | |
| Levorphanol SCHEMBL443051 | 0.99 | CYP2D6 (0.98) | CYP2D6MAPTBLMLMNAHTT | |
| Levorphanol SCHEMBL120615 | 0.99 | CYP2D6 (0.98) | CYP2D6MAPTBLMLMNAHTT | |
| Levorphanol SCHEMBL10688552 | 0.98 | CYP2D6 (0.96) | CYP2D6MAPTBLMLMNAHTT | |
| Levorphanol SCHEMBL31276780 | 0.93 | CYP2D6 (0.87) | CYP2D6MAPTBLMLMNAHTT | |
| Levorphanol SCHEMBL28614888 | 0.92 | OPRD1 (0.89) | CYP2D6MAPTBLMLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1458 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-10851063-B2 | Methods for preparing levorphanol and related compounds, and compositions thereof | AMPAC FINE CHEMICALS LLC (US) | 2020-12-01 | — | — | US | claimed |
| CN-107049932-B | Small molecule drug in-situ phase change gel sustained release system and preparation method thereof | 四川大学 | 2020-11-06 | — | — | CN | claimed |
| US-20200316058-A1 | Opioid Taper Regimen | GROSSMAN JOSEPH LEON (US) | 2020-10-08 | — | — | US | claimed |
| EP-3045043-B1 | EXTENDED RELEASE ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINAN AND METHOD OF USE | RELMADA THERAPEUTICS INC (US) | 2020-04-29 | — | — | EP | claimed |
| US-20200109119-A1 | METHODS FOR PREPARING LEVORPHANOL AND RELATED COMPOUNDS, AND COMPOSITIONS THEREOF | AMPAC FINE CHEMICALS LLC | 2020-04-09 | — | — | US | claimed |
| WO-2018152554-A1 | ANTITUSSIVE COMPOSITIONS AND METHODS | ATTENUA, INC. (US) | 2018-08-23 | — | — | WO | claimed |
| EP-3328383-A1 | ANTITUSSIVE COMPOSITIONS AND METHODS | Attenua, Inc. (US) | 2018-06-06 | — | — | EP | claimed |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERISTY | 2018-03-29 | — | — | US | claimed |
| CN-107847493-A | ANTITUSSIVE COMPOSITIONS AND METHODS | 阿提努公司 | 2018-03-27 | — | — | CN | claimed |
| US-20030100507-A1 | Method and composition for potentiating an opiate analgesic | DONEHEW FUND LIMITED PARTNERSHIP | 2003-05-29 | — | — | US | claimed |
| US-20020151525-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | COLLINS DOUGLAS A (US) | 2002-10-17 | — | — | US | claimed |
| WO-2002055530-A2 | TRANSCOBALAMIN BINDING CONJUGATES USEFUL FOR TREATING ABNORMAL CELLULAR PROLIFERATION | MAYO FOUNDATION (US) | 2002-07-18 | — | — | WO | claimed |
| US-20020044968-A1 | High amount of plasticizer to facilitate plasticization of the matrix material at low shear and then reduced prior to adding the encapsulant to reduce post extrusion | GENERAL MILLS, INC. | 2002-04-18 | — | — | US | claimed |
| US-5061492-A | biodegeadeable polymer matrix is copolymer of gylcolic acid a nd lactic acid | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-10-29 | — | — | US | claimed |
| US-4711782-A | Prolonged release microcapsules and their production | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-12-08 | — | — | US | claimed |
| EP-0046270-B1 | NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | INTERx RESEARCH CORPORATION (US) | 1986-05-21 | — | — | EP | claimed |
| US-4486436-A | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same | ANALGESIC ASSOCIATES (US) | 1984-12-04 | — | — | US | claimed |
| US-4464376-A | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same | RICHARDSON-VICKS, INC. (US) | 1984-08-07 | — | — | US | claimed |
| US-4126684-A | 4-AMINO-3-P-HALOPHENYLBUTYRIC ACIDS AND THEIR DERIVATIVES USED IN THE CONTROL OF NARCOTIC ABUSE | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851063-B2 | Methods for preparing levorphanol and related compounds, and compositions thereof | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885CYP2D6 12/4885MAPT 750/4885 |
| US-20200109119-A1 | METHODS FOR PREPARING LEVORPHANOL AND RELATED COMPOUNDS, AND COMPOSITIONS THEREOF | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885CYP2D6 12/4885MAPT 750/4885 |
| US-20020151525-A1 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | PCNA, MKI67, SLC19A1 | OPRM1 2385/4885CYP2D6 2346/4885MAPT 2973/4885 |
| US-20180085461-A1 | Novel Therapeutic Treatments Using Centhaquin | ADRB3, ADRA2A, ADRB2 | OPRM1 731/4885CYP2D6 4453/4885MAPT 2875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.